Phase 2 trials in New Zealand[12] and Indonesia[9] have shown RV3.BB to be safe, to be as effective as currently deployed vaccines, and to be at least as effective when given from birth as when given from 6 weeks. Surveillance after natural neonatal RV3 infection suggests that one birth dose could be enough.[7] If it is shown to be adequately protective, easier access to children and lower costs of vaccine production and distribution will improve vaccination coverage—and the fear of intussusception will be lessened.

The challenge is to find a mechanism through which to do an ethically appropriate clinical trial of one dose given at birth, of the RV3.BB vaccine and any other suitable candidate vaccines.

Graeme L Barnes
RV3 Rotavirus Vaccine Program, Murdoch Childrens Research Institute, Parkville, VIC 3052, Australia; and Department of Paediatrics, University of Melbourne, and Royal Children's Hospital, Parkville, VIC, Australia
graeme.barnes@rch.org.au

I am named as a co-inventor on an RV3.BB rotavirus vaccine patent. I thank Ruth Bishop, Julie Bines, and members of the RV3 Rotavirus Vaccine Program, who have contributed to the idea that a single dose of RV3.BB rotavirus vaccine given at birth might be sufficient.

1 WHO. Rotavirus vaccines. WHO position paper—January 2013. *Wkly Epidemiol Rec* 2013; **88:** 49–64.
2 Steele AD, Madhi SA, Cunliffe NA, et al. Incidence of rotavirus gastroenteritis by age in African, Asian and European children: relevance for timing of rotavirus vaccination. *Hum Vaccin Immunother* 2016; **12:** 2406–12.
3 Kaye JL. Review of paediatric gastrointestinal physiology data relevant to oral drug delivery. *Int J Clin Pharm* 2011; **33:** 20–24.
4 Prendergast AJ, Kelly P. Interactions between intestinal pathogens, enteropathy and malnutrition in developing countries. *Curr Opin Infect Dis* 2016; **29:** 229–36.
5 Bishop RF, Barnes GL, Cipriani E, Lund JS. Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. *N Engl J Med* 1983; **309:** 72–76.
6 Velazquez FR, Matson DO, Calva JJ, et al. Rotavirus infection in infants as protection against subsequent infections. *N Engl J Med* 1996; **335:** 1022–28.
7 Bines JE, Thobari A, Satria A, et al. Human neonatal rotavirus vaccine (RV3-BB) to target rotavirus from birth. *N Engl J Med* 2018; **378:** 719–30.
8 Vesikari T, Ruuska T, Delem A, Andrea FE. Neonatal rotavirus vaccination with RIT 4237 bovine rotavirus vaccine: a preliminary report. *Pediatr Infect Dis J* 1987; **6:** 164–69.
9 Ruuska T, Vesikari T, Delem A, et al. Evaluation of RIT 4237 bovine rotavirus vaccine in newborn infants: correlation of vaccine efficacy to season of birth in relation to rotavirus epidemic period. *Scand J Infect* Dis 1990; **22:** 269–78.
10 Amah GE, Kapikian AZ, Vesikari T, et al. Efficacy, immunogenicity and safety of two doses of a tetravalent rotavirus vaccine RRV-TV in Ghana with the first dose administered during the neonatal period. *JID* 2013; **208:** 423–31.
11 WHO. Newborns: reducing mortality. www.who.int/mediacentre/factsheets/fs333/en/ (accessed March 30, 2018).
12 Bines JE, Danchin M, Jackson P, et al. Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomized, double-blind, placebo-controlled trial. *Lancet Infect Dis* 2015; **15:** 1389–97.

Corrections

Burki T. David Cooper. Lancet Infect Dis *2018;* ***18:*** *505*—Prof Cooper's mother Annie was born in Leeds, UK; her parents were from Lithuania. The correction has been made to the online version as of May 25, 2018.

Mackenzie GA, Hill PC, Sahito SM, et al. Impact of the introduction of pneumococcal conjugate vaccination on pneumonia in The Gambia: population-based surveillance and case-control studies. Lancet Infect Dis *2017; https://doi.org/10.1016/S1473-3099(17)30321-3*—The open access license for this Article has been corrected to CC BY 4.0. This correction been made to the online version as of June 20, 2018.

Published **Online**
May 25, 2018
http://dx.doi.org/10.1016/S1473-3099(18)30352-9